Published Date: 08 May 2024
New research published in the May issue of The Journal of Nuclear Medicine describes how a novel investigational PET imaging agent can quickly and accurately visualize lesions in patients with clear cell renal cell cancer (ccRCC).
Read Full NewsThe director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).
Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.
Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.
Dietary Diversity With Dairy, Fruit, Grains Linked to Lower Gout Risk
GLPG3667 Meets Primary Endpoint in Dermatomyositis, Misses in SLE Phase 3 Trials
taVNS Reduces Pain, Improves Mood in Fibromyalgia Patients
Metal Exposure Levels May Explain Cardiovascular-Kidney-Metabolic Stages
1.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
2.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
3.
Underprescribed for Alcohol Use Disorder is pharmacotherapy.
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Unlocking the secrets of the fibrotic fortress that surrounds and protects pancreatic cancer
1.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
2.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
3.
HKDC1 Protein: An Emerging Therapeutic Target in Colon Cancer
4.
Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells
5.
Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
4.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation